Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: An update on issues to consider
Oncologist, Volume 15, No. 11, Year 2010
Notification
URL copied to clipboard!
Description
The adjuvant setting of early breast cancer treatment is an evolving field where different modalities must be combined to improve outcomes; moreover, quality of life of breast cancer survivors emerges as a new important parameter to consider, thus implying a better understanding of toxicities of these modalities. We have conducted a review focusing on the latest literature of the past 3 years, trying to evaluate the existing data on the maximum acceptable delay of radiotherapy when given as sole adjuvant treatment after surgery and the optimal sequence of all these modalities with respect to each other. It becomes evident radiotherapy should be given as soon as possible and within a time frame of 6-20 weeks. Chemotherapy is given before radiotherapy and hormone therapy. However, radiotherapy should be started within 7 months after surgery in these cases. Hormone therapy with tamoxifen might be given safely concomitantly or sequentially with radiotherapy although solid data are still lacking. The concurrent administration of letrozole and radiotherapy seems to be safe, whereas data on trastuzumab can imply only that it is safe to use concurrently with radiotherapy. Randomized comparisons of hormone therapy and trastuzumab administration with radiotherapy need to be performed. © AlphaMed Press.
Authors & Co-Authors
Tsoutsou, Pelagia G.
Greece, Komotini
Democritus University of Thrace
Belkacémi, Yazid
France, Creteil
Hôpital Henri Mondor
Gligorov, Joseph
France, Paris
Hôpital Tenon
Kuten, Abraham
Israel, Haifa
Rambam Health Care Campus Israel
Boussen, Hamouda
Tunisia, Ariana
Université de Tunis el Manar, Hôpital Abderrahmène Mami
Beşe, Nuran Şenel
Turkey, Istanbul
İstanbul Tıp Fakültesi
Koukourakis, Michael I.
Greece, Komotini
Democritus University of Thrace
Statistics
Citations: 26
Authors: 7
Affiliations: 6
Identifiers
Doi:
10.1634/theoncologist.2010-0187
ISSN:
10837159
e-ISSN:
1549490X
Research Areas
Cancer
Disability
Health System And Policy